88 related articles for article (PubMed ID: 21604950)
1. Hypofractionation for radiotherapy of prostate cancer using a low alfa/beta ratio--possible reasons for concerns? An example of five dimensional radiotherapy.
Lennernäs B; Nilsson S; Levitt S
Acta Oncol; 2011 Jun; 50 Suppl 1():111-5. PubMed ID: 21604950
[TBL] [Abstract][Full Text] [Related]
2. Four and five dimensional radiotherapy with reference to prostate cancer--definitions, state of the art and further directions--an overview.
Lennernäs B; Castellanos E; Nilsson S; Levitt S
Acta Oncol; 2011 Jun; 50 Suppl 1():104-10. PubMed ID: 21604949
[TBL] [Abstract][Full Text] [Related]
3. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy.
Pieters BR; van de Kamer JB; van Herten YR; van Wieringen N; D'Olieslager GM; van der Heide UA; Koning CC
Radiother Oncol; 2008 Jul; 88(1):46-52. PubMed ID: 18378028
[TBL] [Abstract][Full Text] [Related]
4. Effect of patient variation on standard- and hypo-fractionated radiotherapy of prostate cancer.
Xiong W; Li J; Ma CM
Phys Med Biol; 2005 Apr; 50(7):1483-92. PubMed ID: 15798338
[TBL] [Abstract][Full Text] [Related]
5. Power against prostate cancer. Intensity-modulated radiation therapy and interstitial brachytherapy.
Cash JC
Adv Nurse Pract; 2006 Sep; 14(9):37-42. PubMed ID: 16972442
[No Abstract] [Full Text] [Related]
6. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
[TBL] [Abstract][Full Text] [Related]
7. Extreme hypofractionation for prostate cancer.
Lee WR
Expert Rev Anticancer Ther; 2009 Jan; 9(1):61-5. PubMed ID: 19105707
[TBL] [Abstract][Full Text] [Related]
8. [Prostate cancer].
Vieillot S; Fenoglietto P; Aillères N; Hay MH; Dubois JB; Azria D
Cancer Radiother; 2010 Nov; 14 Suppl 1():S161-73. PubMed ID: 21129660
[TBL] [Abstract][Full Text] [Related]
9. Calculated and simulated effects of heterogeneous dose distributions in radiotherapy using the dose volume inhomogeneity corrected biological equivalent dose formula with special reference to prostate cancer.
Lennernäs B; Albertsson P; Edgren M; Nilsson S
Oncol Rep; 2007 Nov; 18(5):1299-303. PubMed ID: 17914588
[TBL] [Abstract][Full Text] [Related]
10. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.
Martinez AA; Demanes J; Vargas C; Schour L; Ghilezan M; Gustafson GS
Am J Clin Oncol; 2010 Oct; 33(5):481-8. PubMed ID: 19952715
[TBL] [Abstract][Full Text] [Related]
11. Volumetric modulated Arc therapy and conventional intensity-modulated radiotherapy for simultaneous maximal intraprostatic boost: a planning comparison study.
Shaffer R; Morris WJ; Moiseenko V; Welsh M; Crumley C; Nakano S; Schmuland M; Pickles T; Otto K
Clin Oncol (R Coll Radiol); 2009 Jun; 21(5):401-7. PubMed ID: 19268554
[TBL] [Abstract][Full Text] [Related]
12. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
13. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
14. Comparing two strategies of dynamic intensity modulated radiation therapy (dIMRT) with 3-dimensional conformal radiation therapy (3DCRT) in the hypofractionated treatment of high-risk prostate cancer.
Yuen J; Rodrigues G; Trenka K; Coad T; Yartsev S; D'Souza D; Lock M; Bauman G
Radiat Oncol; 2008 Jan; 3():1. PubMed ID: 18179695
[TBL] [Abstract][Full Text] [Related]
15. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer.
Li XA; Wang JZ; Jursinic PA; Lawton CA; Wang D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1251-7. PubMed ID: 15752907
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer treatment with radiotherapy: maturing methods that minimize morbidity.
Pollack A; Zagars GK; Rosen II
Semin Oncol; 1999 Apr; 26(2):150-61. PubMed ID: 10597726
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer.
Aström L; Pedersen D; Mercke C; Holmäng S; Johansson KA
Radiother Oncol; 2005 Feb; 74(2):157-61. PubMed ID: 15734203
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated radiotherapy for favorable risk prostate cancer.
Rene N; Faria S; Cury F; David M; Duclos M; Shenouda G; Souhami L
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):805-10. PubMed ID: 20510194
[TBL] [Abstract][Full Text] [Related]
19. Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer.
Zaider M; Zelefsky MJ; Cohen GN; Chui CS; Yorke ED; Ben-Porat L; Happersett L
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):702-13. PubMed ID: 15708248
[TBL] [Abstract][Full Text] [Related]
20. [Benefit of intensity modulated and image-guided radiotherapy in prostate cancer].
Latorzeff I; Mazurier J; Boutry C; Dudouet P; Richaud P; de Crevoisier R
Cancer Radiother; 2010 Oct; 14(6-7):479-87. PubMed ID: 20797889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
